Ensysce Biosciences (ENSC) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38306
Entity Registrant Name	Ensysce Biosciences, Inc.
Entity Central Index Key	0001716947
Entity Tax Identification Number	82-2755287
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7946 Ivanhoe Avenue
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	(858)
Local Phone Number	263-4196
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,560,952
Common Stock [Member]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ENSC
Security Exchange Name	NASDAQ
Warrants [Member]
Title of 12(b) Security	Warrants to purchase one share of Common Stock
Trading Symbol	ENSCW

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 8,440,952	$ 12,264,736
Unbilled receivable	808,601	441,721
Right-of-use asset	17,609	24,721
Prepaid expenses and other current assets	2,391,240	2,931,415
Total current assets	11,658,402	15,662,593
Property and equipment, net
Other assets	713,090	754,756
Total assets	12,371,492	16,417,349
Current liabilities:
Accounts payable	959,630	301,104
Accrued expenses and other liabilities	1,751,506	3,407,533
Lease liability	17,716	24,874
Notes payable and accrued interest ($6,073,057 and $12,358,886 at fair value at March 31, 2022 and December 31, 2021, respectively)	6,073,057	12,748,155
Total current liabilities	8,801,909	16,481,666
Long-term liabilities:
Notes payable, net of current portion (at fair value)	1,586,901	4,440,951
Other long-term liabilities	871,409	3,652,790
Total long-term liabilities	2,458,310	8,093,741
Total liabilities	11,260,219	24,575,407
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2022 (unaudited) and December 31, 2021
Common stock, $0.0001 par value, 150,000,000 shares authorized; 29,968,787 and 24,662,904 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 29,949,032 and 24,643,149 shares outstanding at March 31, 2022 (unaudited) and December 31, 2021, respectively	2,995	2,464
Additional paid-in capital	88,900,164	77,964,860
Accumulated deficit	(87,512,253)	(85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)	1,390,906	(7,878,243)
Noncontrolling interests in stockholders’ equity (deficit)	(279,633)	(279,815)
Total stockholders’ equity (deficit)	1,111,273	(8,158,058)
Total liabilities and stockholders’ equity (deficit)	$ 12,371,492	$ 16,417,349

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Fair value of notes payable, current	$ 6,073,057	$ 12,358,886
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	29,968,787	24,662,904
Common stock, shares outstanding	29,949,032	24,643,149

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Federal grants	$ 603,098	$ 250,576
Operating expenses:
Research and development	3,140,096	284,378
General and administrative	2,265,806	490,471
Total operating expenses	5,405,902	774,849
Loss from operations	(4,802,804)	(524,273)
Other income (expense):
Change in fair value of derivative liabilities		(39,585)
Change in fair value of convertible notes	2,767,178
Change in fair value of liability classified warrants	2,794,398
Loss on debt conversions	(1,702,642)
Interest expense	(15,021)	(347,834)
Other income and expense, net	7,966
Total other income (expense), net	3,851,879	(387,419)
Net income (loss)	(950,925)	(911,692)
Net income (loss) attributable to noncontrolling interests	182	(3,961)
Deemed dividend related to warrants down round provision	715,579
Net loss attributable to common stockholders	$ (1,666,686)	$ (907,731)
Net loss per share:
Net loss per share attributable to common stockholders, basic and diluted	$ (0.06)	$ (0.06)
Weighted average common shares outstanding, basic and diluted	27,287,618	15,834,185

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Previously Reported [Member]Common Stock [Member]	Previously Reported [Member]Additional Paid-in Capital [Member]	Previously Reported [Member]Retained Earnings [Member]	Previously Reported [Member]Noncontrolling Interest [Member]	Previously Reported [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 5,987	$ 49,511,927	$ (55,958,716)	$ (217,625)	$ (6,658,427)
Balance, shares at Dec. 31, 2019	239,465,160
Retroactive application of recapitalization	$ (4,410)	$ 4,410
Retroactive application of recapitalization, shares	(223,696,435)
Balance at Dec. 31, 2020						$ 1,577	$ 49,516,337	$ (55,958,716)	$ (217,625)	$ (6,658,427)
Balance, shares at Dec. 31, 2020						15,768,725
Exercise of stock options						$ 28	262,834			262,862
Exercise of stock options, shares						284,825
Stock-based compensation							43,820			43,820
Net loss								(907,731)	(3,961)	(911,692)
Balance at Mar. 31, 2021						$ 1,605	49,822,991	(56,866,447)	(221,586)	(7,263,437)
Balance, shares at Mar. 31, 2021						16,053,550
Balance at Dec. 31, 2021						$ 2,464	77,964,860	(85,845,567)	(279,815)	$ (8,158,058)
Balance, shares at Dec. 31, 2021						24,643,149
Exercise of stock options, shares
Stock-based compensation							2,090,663			$ 2,090,663
Net loss								(951,107)	182	(950,925)
Consultant compensation						$ 5	54,245			54,250
Consultant compensation, shares						50,000
Conversions of convertible notes						$ 471	8,074,872			8,075,343
Conversions of convertible notes, shares						4,708,525
Settlement of restricted stock units						$ 55	(55)
Settlement of restricted stock units, shares						547,358
Deemed dividend related to warrants down round provision							715,579	(715,579)
Balance at Mar. 31, 2022						$ 2,995	$ 88,900,164	$ (87,512,253)	$ (279,633)	$ 1,111,273
Balance, shares at Mar. 31, 2022						29,949,032

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (950,925)	$ (911,692)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		51
Gain on sale of asset	(4,500)
Accrued interest	15,021	173,422
Accretion of discounts on promissory notes		174,413
Change in fair value of embedded derivative		39,586
Change in fair value of liability classified warrants	(2,794,398)
Change in fair value of convertible notes	(2,767,178)
Stock-based compensation	402,434	43,820
Lease cost	(46)	(589)
Loss on debt conversions	1,702,642
Changes in operating assets and liabilities:
Unbilled receivable	(366,880)
Prepaid expenses and other assets	581,840	51,244
Accounts payable	658,526	(92,184)
Accrued expenses and other liabilities	86,450	4,780
Net cash used in operating activities	(3,437,014)	(517,149)
Cash flows from investing activities:
Proceeds from sale of asset	4,500
Net cash provided by investing activities	4,500
Cash flows from financing activities:
Proceeds from issuance of promissory notes		50,000
Proceeds from issuance of promissory notes to related parties		300,000
Proceeds from exercise of stock options		262,862
Repayment of financed insurance premiums	(391,270)
Net cash (used in) provided by financing activities	(391,270)	612,862
Increase (decrease) in cash and cash equivalents	(3,823,784)	95,713
Cash and cash equivalents beginning of period	12,264,736	194,214
Cash and cash equivalents end of period	8,440,952	289,927
Supplemental cash flow information:
Income tax payments		1,600
Supplemental disclosure of non-cash investing and financing activities:
Fair value of embedded derivative at issuance		3,052
Deferred transaction costs in accounts payable		596,975
Deferred transaction costs in accrued expenses and other liabilities		200,927
Stock-based compensation	1,742,479
Conversions of convertible notes into common stock	6,372,701
Deemed dividend related to warrants down round provision	$ 715,579

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Ensysce Biosciences, Inc. (“Ensysce”), along with its subsidiary, Covistat Inc. (“Covistat”) and its wholly owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its two novel proprietary technology platforms to develop what the Company believe to be safer prescription drugs. The primary focus of the Company is developing abuse and overdose resistant pain drugs, with a clinical stage program for the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR TM TM On January 31, 2021, Leisure Acquisition Corp., a Delaware corporation (“LACQ”), entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Ensysce Biosciences, Inc., a Delaware corporation (“Former Ensysce”), and EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of LACQ (“Merger Sub”). Pursuant to the Merger Agreement, on June 30, 2021 (the “Closing Date”), Merger Sub was merged with and into Former Ensysce, with Former Ensysce surviving the merger (“Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the closing of the Business Combination on the Closing Date (the “Closing”), Former Ensysce became a wholly owned subsidiary of LACQ and the stockholders of Former Ensysce, as of immediately prior to the effective time of the Merger, received shares of LACQ and hold a portion of the shares of Common Stock, par value $ 0.0001 On the Closing Date, at the effective time of the Merger, LACQ changed its name from “Leisure Acquisition Corp.” to “Ensysce Biosciences, Inc.” Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Ensysce and the combined company and its subsidiaries following the Closing. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing. In connection with the Business Combination, outstanding shares of common stock of Former Ensysce (including shares resulting from the conversion of Former Ensysce’s convertible debt prior to Closing) were converted into the right to receive shares of Ensysce at an exchange ratio of 0.06585 71.8% In June 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, Covistat, Inc., a Delaware corporation. Pursuant to the articles of incorporation, Covistat was authorized to issue 1,000,000 0.001 100,000 0.001 79.2% 19.8% 1.0% In March 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic”. First identified in late 2019 and known now as COVID-19, the outbreak has impacted millions of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations. The Company’s operations have not been significantly impacted; however, the Company continues to monitor the situation. No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred as of year-end; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future. In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time. The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022. Business Combination The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $ 7.8 1.1 0.06585 Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue and had an accumulated deficit of $ 87.5 million at March 31, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In December 2020, the Company executed a share subscription facility with an investment group. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $ 60.0 1,106,108 10.01 1.2 800,000 400,000 In September 2021, the Company entered into a $ 15.9 The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates and Assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable. Cash and Cash Equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss. Property and Equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No 51 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet. Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021, the Company issued convertible notes with a face value of $ 15.9 Warrants In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8. The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE March 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 7,659,958 $ - $ - $ 7,659,958 Liability classified warrants 509,190 - - 509,190 Total $ 8,169,148 $ $ $ 8,169,148 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ $ $ 20,103,425 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible notes Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Conversions (6,372,701 ) (6,372,701 ) - Change in fair value (5,561,576 ) (2,767,178 ) (2,794,398 ) Fair value, March 31, 2022 $ 8,169,148 $ 7,659,958 $ 509,190 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS Three Months Ended March 31, 2022 2021 MPAR $ 504,470 $ 73,726 OUD 98,628 176,850 Total $ 603,098 $ 250,576 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded. Research and Development Costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. General and Administrative Expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees. Stock-based Compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Earnings per Share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows: SCHEDULE OF EARNINGS PER SHARE RECONCILIATION Three Months Ended March 31, 2022 2021 Numerator: Net income (loss) attributable to common stockholders $ (1,666,686 ) $ (907,731 ) Denominator: Weighted average shares outstanding, basic 27,287,618 15,834,185 Weighted average dilutive stock options - - Weighted average shares outstanding, diluted 27,287,618 15,834,185 Net income (loss) per share attributable to common stockholders, basic and diluted $ (0.06 ) $ (0.06 ) The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES Three Months Ended March 31, 2022 2021 Stock options 5,786,814 4,614,059 Warrants 21,090,873 19,755 Total 26,877,687 4,633,814 Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, December 31, 2022 2021 Prepaid insurance $ 1,793,164 $ 2,124,008 Prepaid research and development 455,472 733,234 Other prepaid expenses 142,604 74,173 Total prepaid expenses and other current assets $ 2,391,240 $ 2,931,415

ACCRUED EXPENSES AND OTHER LIAB

ACCRUED EXPENSES AND OTHER LIABILITIES	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES March 31, December 31, 2022 2021 Share subscription facility commitment fees $ 800,000 $ 800,000 Accrued research and development 398,618 388,997 Professional fees 266,228 138,086 Bonus accrual 134,413 610,000 Accrued scientific advisory board fees 60,032 60,032 Consultant stock compensation expenses - 1,342,479 Other accrued liabilities 92,215 67,939 Total accrued expenses and other liabilities $ 1,751,506 $ 3,407,533 Other long-term liabilities consisted of the following: SCHEDULE OF OTHER LONG-TERM LIABILITIES 2022 2021 March 31, December 31, 2022 2021 Share subscription facility commitment fees $ 362,219 $ 349,202 Liability classified warrants 509,190 3,303,588 Total other long-term liabilities $ 871,409 $ 3,652,790

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6 - COMMITMENTS AND CONTINGENCIES Purchase Commitments As of March 31, 2022, the Company’s commitments included an estimated $ 15.8 million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services. Litigation As of March 31, 2022 and December 31, 2021, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Lease In August 2020, the Company entered into an agreement to lease office space. The lease commencement date was October 1, 2020 and was subsequently amended to extend the term of the lease through October 31, 2022 with no option to renew. The amendment resulted in a modification of the lease under ASC 842 and the Company remeasured the lease liability as of the amendment date. As of March 31, 2022, the future lease payments totaled $ 17,716 The Company recognized total rent expense of $ 7,834 12,379 Compensation Subject to Shareholder Approval In July 2021, the Company engaged two consultants to perform certain public and investor relations services in consideration for warrants to purchase 500,000 shares of common stock with a five-year term and an exercise price of $ 6.28 each, 50,000 shares of common stock each, and 200,000 restricted stock units each. The restricted stock units vest over one year 50% and 50% contingent upon certain market conditions. These equity awards were contingent upon shareholder approval of an amended and restated 2021 Omnibus Plan at a special shareholder meeting in January 2022, whereby the warrants were replaced by non-qualified stock options with similar terms. As the original terms of the awards did not satisfy the grant date criteria for an equity award, as of December 31, 2021, the Company recorded a liability $ 1,342,479 to reflect the estimated value of services received during the period. On February 14, 2022, the equity awards were granted, and the Company reclassified the outstanding liability to stockholders’ equity. During the three months ended March 31, 2022 the Company reclassified the existing balance of the liability to equity and recorded an additional $ 87,208 of consultant compensation to general and administrative expense as a result of the vesting schedule of the restricted stock units.

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 - NOTES PAYABLE The following table provides a summary of the Company’s outstanding debt as of March 31, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair value adjustment Net debt balance 2021 Notes $ 7,627,778 $ 78,509 $ (46,329 ) $ 7,659,958 Total $ 7,627,778 $ 78,509 $ (46,329 ) $ 7,659,958 The following table provides a summary of the Company’s outstanding debt as of December 31, 2021: Principal balance Accrued interest Fair value Adjustment Net debt balance 2021 Notes $ 13,647,341 $ 159,435 $ 2,993,061 $ 16,799,837 Finance Insurance 385,187 4,082 - 389,269 Total $ 14,032,528 $ 163,517 $ 2,993,061 $ 17,189,106 The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows: SCHEDULE OF INTEREST EXPENSE DEBT 2022 2021 Three months ended March 31, 2022 2021 Stated interest accrual $ 2,004 $ 109,381 Debt discount amortization - 174,412 Total $ 2,004 $ 283,793 2021 Notes On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provides for two closings: the first closing for $ 5.3 4.6 10.6 9.4 The proceeds of the 2021 Notes shall be used for working capital purposes subject to certain customary restrictions and secured by the Company’s rights to its patents and licenses. The Company may not issue any additional debt or equity without the prior written consent of the holders. The 2021 Notes mature on June 23, 2023 August 4, 2023 5% 6% The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $ 15.9 million. The Company recorded total issuance costs of $ 1.9 million representing investment banking and legal fees of $ 1.0 million and original issue discounts of $ 0.9 million. After multiple conversions since issuance, the Company remeasured the fair value as of March 31, 2022 and recognized a gain of $ 2.8 million as the fair value of the 2021 Notes had decreased to $ 7.7 million due to a decrease in the value of the conversion option resulting from a decrease in the price of the Company’s common stock. The March 31, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an 8% cash settlement premium) and thus a separate amount is not reflected on the consolidated statements of operations. If presented separately, the total amount of interest expense (after consideration of the conversions) at March 31, 2022 would be $ 123,220 . The 2021 Notes may be converted into the Company’s common stock at the option of the holder in whole or in part at the conversion price of $ 5.87 beneficial ownership limitation of 4.99% At the Company’s option, the Company may redeem some or all of the then-outstanding principal amount of the 2021 Notes for cash in an amount equal to 100% of the principal to be redeemed, plus accrued but unpaid interest, plus all other amounts due with respect to the 2021 Notes. Beginning January 1, 2022 for the First Closing, and February 1, 2022 for the Second Closing, and the first of each subsequent month, terminating upon the full redemption of the 2021 Notes (each a “Monthly Redemption Date”), the Company shall redeem the Monthly Redemption Amount (defined below), payable in cash or shares. The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) 92% 0.78 The Monthly Redemption Amount is defined as 1/18 th If, at any time while the 2021 Notes are outstanding, the Company carries out one or more capital raises in excess of $ 5.0 20% The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022: SCHEDULE OF CONVERSIONS DEBT Shares Conversion Price Conversion Value January 3, 2022 535,249 $ 2.83 $ 1,517,054 February 3, 2022 1,354,423 $ 1.58 2,145,135 March 1, 2022 2,818,853 $ 0.96 2,710,512 Total 4,708,525 $ 6,372,701 During the three months ending March 31, 2022, the company recognized $ 1.7 million of loss on debt conversions related to the monthly conversions, resulting from the difference between the conversion price and the average of the high and low stock price on the date of conversion. Such expense is reported under other income (expense), net in the consolidated statements of operations. Financed insurance premiums During the year ended December 31, 2021, the Company financed its director and officer liability insurance in the amount of $ 867,300 2,004

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 - STOCKHOLDERS’ EQUITY In June 2021, in connection with the Business Combination, the Company amended and restated its Certificate of Incorporation to authorize 150,000,000 1,500,000 0.0001 no Common Stock On June 30, 2021, in connection with the Closing, the following common stock activity occurred: ● 16,053,550 ● 6,219,268 ● 1,357,968 5.8 ● 19,755 ● 500,000 ● 125,000 Warrants On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 18,901,290 $ 10.00 11.50 LACQ warrants Equity (b) 1,106,108 $ 0.96 Share subscription facility Equity (c) 361,158 $ 7.63 Convertible note Liability (d) 722,317 $ 7.63 Convertible note Liability 21,090,873 a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 10.00 11.50 June 30, 2026 10,000,000 8,901,290 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 500,000 warrants issued on June 30, 2021 from $ 11.50 to $ 10.00. b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 three 10.01 14.49 11.6 On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $ 4.50 2.83 1.58 0.96 c) On September 24, 2021, the Company issued 361,158 7.63 September 23, 2026 d) On November 5, 2021, the Company issued 722,317 7.63 November 4, 2026 The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (a) LACQ warrants (grant date varies) (b) Share subscription facility (grant date 7/2/2021) (b) Share subscription facility (remeasurement date varies) Stock price $ 14.49 $ 14.49 $ 1.26 - 4.29 Exercise price $ 10.0 11.50 $ 10.01 $ 0.96 2.83 Expected term (years) 3.00 3.00 2.34 2.49 Volatility 110.0 % 110.0 % 113.8 117.2 Risk free rate 0.5 % 0.5 % 1.04 1.47 (c) Liability classified warrants (grant date 9/24/2021) (c) Liability classified warrants (remeasured at 3/31/22) (d) Liability classified warrants (grant date 11/5/2021) (d) Liability classified warrants (remeasured at 3/31/22) Stock price $ 4.49 $ 1.14 $ 2.25 $ 1.14 Exercise price $ 7.63 $ 7.63 $ 7.63 $ 7.63 Expected term (years) 5.00 4.50 5.00 4.60 Volatility 94.1 % 99.4 % 94.1 % 98.6 % Risk free rate 1.0 % 2.4 % 1.0 % 2.4 %

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 - STOCK-BASED COMPENSATION In 2016, Former Ensysce adopted the Ensysce Biosciences, Inc. 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan, as amended, allowed for the issuance of non-statutory stock options, incentive stock options and other equity awards to Former Ensysce’s employees, directors, and consultants. In March 2019, Former Ensysce adopted the 2019 Directors Plan, which was amended in August 2020. The 2019 Directors Plan, as amended, allowed for the issuance of shares of Former Ensysce’s common stock pursuant to the grant of non-statutory stock options. In addition to the 2016 Plan and the 2019 Directors Plan, the Company has two legacy equity incentive plans (the “Legacy Plans”). No additional equity awards may be made under the Legacy Plans and the outstanding options will expire if unexercised by certain dates through August 2024. In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the 4,444,068 1,000,000 3,000,000 The Company recognized within general and administrative expense stock-based compensation expense of $ 373,944 43,820 28,490 0 Option Activity During the three months ended March 31, 2022, the Company granted stock options to purchase an aggregate of 1,986,000 shares of common stock to employees, consultants and members of the Board. The options vest over periods between 0 and 4 years and have an exercise price of between $ 1.08 and $ 6.28 per share. There were no stock option grants in 2021. The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual Intrinsic value Outstanding at December 31, 2021 4,444,068 $ 2.40 6.00 $ 10,207,306 Granted 1,986,000 4.33 - - Exercised - - - - Expired / Forfeited - - - - Outstanding at March 31, 2022 6,430,068 3.00 7.02 960 Exercisable at March 31, 2022 5,469,714 3.11 6.54 - Vested and expected to vest 6,430,068 3.00 7.02 960 Option Valuation The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Three Months Ended March 31, 2022 Stock price $ 1.08 1.61 Exercise price $ 1.08 6.28 Expected stock price volatility 76.12 - 95.87% Expected term (years) 5.19 – 10.00 Risk-free interest rate 1.52 % - 2.20 % Expected dividend yield 0% ● Expected stock-price volatility. ● Expected term. ● Risk-free interest rate. ● Expected dividend yield. The weighted-average grant date fair value of options granted during the three months ended March 31, 2022 was $ 1.01 As of March 31, 2022, the Company had an aggregate of $ 924,175 of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of 1.6 years. Restricted Stock Units During the three months ended March 31, 2022, the Company granted 927,358 restricted stock unit (“RSU”) awards (weighted-average fair value per share of $ 1.04 547,358 shares of common stock for vested RSU awards (weighted average fair value per share of $ 1.23 50,000 RSU awards. The remaining 330,000 RSU awards (weighted average fair value per share of $ 0.88 Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE March 31, 2022 Awards outstanding under the 2021 Omnibus Incentive Plan 6,760,068 Awards available for future grant under 2021 Omnibus Incentive Plan 1,136,642 Warrants outstanding 21,090,873 Total shares of common stock reserved for future issuance 28,987,583

RELATED PARTIES

RELATED PARTIES	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 10 - RELATED PARTIES The Company paid cash compensation during the three months ended March 31, 2021 of $ 33,146 no

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 - SUBSEQUENT EVENTS In the second quarter of 2022, in connection with the monthly redemption schedule (described in Note 7), the Company issued 4,511,920 shares of common stock as a result of monthly conversions of $ 4.3 million of the 2021 Notes.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of common stock, warrants, options to purchase the Company’s common stock, and the notes payable.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Concentrations of credit risk and off-balance sheet risk	Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.
Property and Equipment	Property and Equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five to six years. No 51 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the three months ended March 31, 2022 and 2021.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.
Fair Value Measurement	Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.
2021 Notes	2021 Notes In 2021, the Company issued convertible notes with a face value of $ 15.9
Warrants	Warrants In 2021, the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8. The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE March 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 7,659,958 $ - $ - $ 7,659,958 Liability classified warrants 509,190 - - 509,190 Total $ 8,169,148 $ $ $ 8,169,148 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ $ $ 20,103,425 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible notes Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Conversions (6,372,701 ) (6,372,701 ) - Change in fair value (5,561,576 ) (2,767,178 ) (2,794,398 ) Fair value, March 31, 2022 $ 8,169,148 $ 7,659,958 $ 509,190
Federal Grants	Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS Three Months Ended March 31, 2022 2021 MPAR $ 504,470 $ 73,726 OUD 98,628 176,850 Total $ 603,098 $ 250,576 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.
Research and Development Costs	Research and Development Costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.
Stock-based Compensation	Stock-based Compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2022 and 2021, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.
Income Taxes	Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Earnings per Share	Earnings per Share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows: SCHEDULE OF EARNINGS PER SHARE RECONCILIATION Three Months Ended March 31, 2022 2021 Numerator: Net income (loss) attributable to common stockholders $ (1,666,686 ) $ (907,731 ) Denominator: Weighted average shares outstanding, basic 27,287,618 15,834,185 Weighted average dilutive stock options - - Weighted average shares outstanding, diluted 27,287,618 15,834,185 Net income (loss) per share attributable to common stockholders, basic and diluted $ (0.06 ) $ (0.06 ) The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES Three Months Ended March 31, 2022 2021 Stock options 5,786,814 4,614,059 Warrants 21,090,873 19,755 Total 26,877,687 4,633,814
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. On January 1, 2022, the Company adopted ASU 2019-12 and did not have a significant impact on the consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company is evaluating the impact of ASU 2020-06 on the consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE	The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of March 31, 2022 and December 31, 2021. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE March 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 7,659,958 $ - $ - $ 7,659,958 Liability classified warrants 509,190 - - 509,190 Total $ 8,169,148 $ $ $ 8,169,148 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ $ $ 20,103,425
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3	The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible notes Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Conversions (6,372,701 ) (6,372,701 ) - Change in fair value (5,561,576 ) (2,767,178 ) (2,794,398 ) Fair value, March 31, 2022 $ 8,169,148 $ 7,659,958 $ 509,190
SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS	The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS Three Months Ended March 31, 2022 2021 MPAR $ 504,470 $ 73,726 OUD 98,628 176,850 Total $ 603,098 $ 250,576
SCHEDULE OF EARNINGS PER SHARE RECONCILIATION	SCHEDULE OF EARNINGS PER SHARE RECONCILIATION Three Months Ended March 31, 2022 2021 Numerator: Net income (loss) attributable to common stockholders $ (1,666,686 ) $ (907,731 ) Denominator: Weighted average shares outstanding, basic 27,287,618 15,834,185 Weighted average dilutive stock options - - Weighted average shares outstanding, diluted 27,287,618 15,834,185 Net income (loss) per share attributable to common stockholders, basic and diluted $ (0.06 ) $ (0.06 )
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES	The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES Three Months Ended March 31, 2022 2021 Stock options 5,786,814 4,614,059 Warrants 21,090,873 19,755 Total 26,877,687 4,633,814

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses And Other Current Assets
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, December 31, 2022 2021 Prepaid insurance $ 1,793,164 $ 2,124,008 Prepaid research and development 455,472 733,234 Other prepaid expenses 142,604 74,173 Total prepaid expenses and other current assets $ 2,391,240 $ 2,931,415

ACCRUED EXPENSES AND OTHER LI_2

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES	Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES March 31, December 31, 2022 2021 Share subscription facility commitment fees $ 800,000 $ 800,000 Accrued research and development 398,618 388,997 Professional fees 266,228 138,086 Bonus accrual 134,413 610,000 Accrued scientific advisory board fees 60,032 60,032 Consultant stock compensation expenses - 1,342,479 Other accrued liabilities 92,215 67,939 Total accrued expenses and other liabilities $ 1,751,506 $ 3,407,533
SCHEDULE OF OTHER LONG-TERM LIABILITIES	Other long-term liabilities consisted of the following: SCHEDULE OF OTHER LONG-TERM LIABILITIES 2022 2021 March 31, December 31, 2022 2021 Share subscription facility commitment fees $ 362,219 $ 349,202 Liability classified warrants 509,190 3,303,588 Total other long-term liabilities $ 871,409 $ 3,652,790

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
SCHEDULE OF DEBT	The following table provides a summary of the Company’s outstanding debt as of March 31, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair value adjustment Net debt balance 2021 Notes $ 7,627,778 $ 78,509 $ (46,329 ) $ 7,659,958 Total $ 7,627,778 $ 78,509 $ (46,329 ) $ 7,659,958 The following table provides a summary of the Company’s outstanding debt as of December 31, 2021: Principal balance Accrued interest Fair value Adjustment Net debt balance 2021 Notes $ 13,647,341 $ 159,435 $ 2,993,061 $ 16,799,837 Finance Insurance 385,187 4,082 - 389,269 Total $ 14,032,528 $ 163,517 $ 2,993,061 $ 17,189,106
SCHEDULE OF INTEREST EXPENSE DEBT	The interest expense recognized for notes payable (excluding the 2021 Notes) was as follows: SCHEDULE OF INTEREST EXPENSE DEBT 2022 2021 Three months ended March 31, 2022 2021 Stated interest accrual $ 2,004 $ 109,381 Debt discount amortization - 174,412 Total $ 2,004 $ 283,793
SCHEDULE OF CONVERSIONS DEBT	The following table provides a summary of the Company’s 2021 Notes conversions during the three months period ending March 31, 2022: SCHEDULE OF CONVERSIONS DEBT Shares Conversion Price Conversion Value January 3, 2022 535,249 $ 2.83 $ 1,517,054 February 3, 2022 1,354,423 $ 1.58 2,145,135 March 1, 2022 2,818,853 $ 0.96 2,710,512 Total 4,708,525 $ 6,372,701

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
SCHEDULE OF OUTSTANDING WARRANT	On March 31, 2022, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 18,901,290 $ 10.00 11.50 LACQ warrants Equity (b) 1,106,108 $ 0.96 Share subscription facility Equity (c) 361,158 $ 7.63 Convertible note Liability (d) 722,317 $ 7.63 Convertible note Liability 21,090,873 a) On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 10.00 11.50 June 30, 2026 10,000,000 8,901,290 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the exercise price of 500,000 warrants issued on June 30, 2021 from $ 11.50 to $ 10.00. b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 three 10.01 14.49 11.6 On December 28, 2021, January 3, 2022, February 1, 2022 and March 1, 2022 the exercise price of the warrants adjusted to $ 4.50 2.83 1.58 0.96 c) On September 24, 2021, the Company issued 361,158 7.63 September 23, 2026 d) On November 5, 2021, the Company issued 722,317 7.63 November 4, 2026
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS	The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (a) LACQ warrants (grant date varies) (b) Share subscription facility (grant date 7/2/2021) (b) Share subscription facility (remeasurement date varies) Stock price $ 14.49 $ 14.49 $ 1.26 - 4.29 Exercise price $ 10.0 11.50 $ 10.01 $ 0.96 2.83 Expected term (years) 3.00 3.00 2.34 2.49 Volatility 110.0 % 110.0 % 113.8 117.2 Risk free rate 0.5 % 0.5 % 1.04 1.47 (c) Liability classified warrants (grant date 9/24/2021) (c) Liability classified warrants (remeasured at 3/31/22) (d) Liability classified warrants (grant date 11/5/2021) (d) Liability classified warrants (remeasured at 3/31/22) Stock price $ 4.49 $ 1.14 $ 2.25 $ 1.14 Exercise price $ 7.63 $ 7.63 $ 7.63 $ 7.63 Expected term (years) 5.00 4.50 5.00 4.60 Volatility 94.1 % 99.4 % 94.1 % 98.6 % Risk free rate 1.0 % 2.4 % 1.0 % 2.4 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes the Company’s stock option activity during the three months ended March 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual Intrinsic value Outstanding at December 31, 2021 4,444,068 $ 2.40 6.00 $ 10,207,306 Granted 1,986,000 4.33 - - Exercised - - - - Expired / Forfeited - - - - Outstanding at March 31, 2022 6,430,068 3.00 7.02 960 Exercisable at March 31, 2022 5,469,714 3.11 6.54 - Vested and expected to vest 6,430,068 3.00 7.02 960
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS	The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Three Months Ended March 31, 2022 Stock price $ 1.08 1.61 Exercise price $ 1.08 6.28 Expected stock price volatility 76.12 - 95.87% Expected term (years) 5.19 – 10.00 Risk-free interest rate 1.52 % - 2.20 % Expected dividend yield 0%
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE	The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE March 31, 2022 Awards outstanding under the 2021 Omnibus Incentive Plan 6,760,068 Awards available for future grant under 2021 Omnibus Incentive Plan 1,136,642 Warrants outstanding 21,090,873 Total shares of common stock reserved for future issuance 28,987,583

ORGANIZATION AND PRINCIPAL AC_2

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Jan. 31, 2021	Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Preferred stock, shares authorized	1,500,000	1,500,000	1,500,000
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Former Ensysce [Member]
Restructuring Cost and Reserve [Line Items]
Common stock, par value				$ 0.0001
Debt instrument, conversion price	$ 0.06585			$ 0.06585
Ownership percentage				71.80%
Covistat [Member]
Restructuring Cost and Reserve [Line Items]
Common stock, par value					$ 0.001
Ownership percentage					79.20%
Common stock, shares authorized					1,000,000
Preferred stock, shares authorized					100,000
Preferred stock, par value					$ 0.001
Covistat [Member] | Key Personnel [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage					19.80%
Covistat [Member] | Unrelated Party [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage					1.00%

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)

1 Months Ended

Jun. 30, 2021

Mar. 31, 2022

Mar. 01, 2022

Feb. 01, 2022

Jan. 03, 2022

Dec. 31, 2021

Dec. 28, 2021

Nov. 05, 2021

Sep. 30, 2021

Sep. 24, 2021

Jan. 31, 2021

Dec. 31, 2020

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Accumulated deficit

$ 87,512,253

$ 85,845,567

Common stock, subscriptions value

$ 6,000,000

Warrants issued

18,901,290

722,317

361,158

Warrant, exercise price

$ 0.96

$ 1.58

$ 2.83

$ 4.50

$ 7.63

$ 7.63

Debt instrument, face amount

7,627,778

$ 14,032,528

Convertible Note Financing Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Debt instrument, face amount

$ 15,900,000

Investor [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants issued

1,106,108

Warrant, exercise price

$ 10.01

Commitment fees

$ 1,200,000

Investor [Member] | First Anniversary [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Commitment fees

800,000

Investor [Member] | 18 Month Anniversary [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Commitment fees

$ 400,000

Former Ensysce [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Cash

7,800,000

Prepaid expense

$ 1,100,000

Debt Instrument, conversion price

$ 0.06585

$ 0.06585

SCHEDULE OF ASSETS AND LIABILIT

SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note	$ 7,659,958	$ 16,799,837
Liability classified warrants	509,190	3,303,588
Total	8,169,148	20,103,425
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note	7,659,958	16,799,837
Liability classified warrants	509,190	3,303,588
Total	$ 8,169,148	$ 20,103,425

SCHEDULE OF CHANGE IN FAIR VALU

SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 20,103,425
Conversions	(6,372,701)
Change in fair value	(5,561,576)
Ending balance	8,169,148
Convertible notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	16,799,837
Conversions	(6,372,701)
Change in fair value	(2,767,178)
Ending balance	7,659,958
Liability classified warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	3,303,588
Conversions
Change in fair value	(2,794,398)
Ending balance	$ 509,190

SCHEDULE OF REVENUE RECOGNIZATI

SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Product Information [Line Items]
Total	$ 603,098	$ 250,576
MPAR [Member]
Product Information [Line Items]
Total	504,470	73,726
OUD [Member]
Product Information [Line Items]
Total	$ 98,628	$ 176,850

SCHEDULE OF EARNINGS PER SHARE

SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net income (loss) attributable to common stockholders	$ (1,666,686)	$ (907,731)
Denominator:
Weighted average shares outstanding, basic	27,287,618	15,834,185
Weighted average dilutive stock options
Weighted average shares outstanding, diluted	27,287,618	15,834,185
Net income (loss) per share attributable to common stockholders, basic and diluted	$ (0.06)	$ (0.06)

SCHEDULE OF WEIGHTED AVERAGE SH

SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	26,877,687	4,633,814
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,786,814	4,614,059
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	21,090,873	19,755

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jun. 30, 2021	Sep. 30, 2019	Aug. 31, 2019	Sep. 30, 2018
Depreciation expense		$ 51
Proceeds from issuance of debt			$ 15,900,000
Grants receivable					$ 5,400,000	$ 5,100,000	$ 5,400,000
Year 1 [Member]
Grants receivable						2,100,000	3,200,000
Contribution of grants							1,100,000
Year 2 [Member]
Grants receivable						$ 3,000,000	$ 2,200,000
Year 3 [Member]
Grants receivable				$ 2,800,000

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Prepaid insurance	$ 1,793,164	$ 2,124,008
Prepaid research and development	455,472	733,234
Other prepaid expenses	142,604	74,173
Total prepaid expenses and other current assets	$ 2,391,240	$ 2,931,415

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Share subscription facility commitment fees	$ 800,000	$ 800,000
Accrued research and development	398,618	388,997
Professional fees	266,228	138,086
Bonus accrual	134,413	610,000
Accrued scientific advisory board fees	60,032	60,032
Consultant stock compensation expenses		1,342,479
Other accrued liabilities	92,215	67,939
Total accrued expenses and other liabilities	$ 1,751,506	$ 3,407,533

SCHEDULE OF OTHER LONG-TERM LIA

SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Total other long-term liabilities	$ 871,409	$ 3,652,790
Commitment Fees [Member]
Total other long-term liabilities	362,219	349,202
Warrant Liabilities [Member]
Total other long-term liabilities	$ 509,190	$ 3,303,588

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 01, 2022	Feb. 01, 2022	Jan. 03, 2022	Dec. 31, 2021	Dec. 28, 2021	Nov. 05, 2021	Sep. 24, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Contractual obligation		$ 15,800,000
Operating lease, payments		17,716
Rent expense		7,834	$ 12,379
Warrant, exercise price				$ 0.96	$ 1.58	$ 2.83		$ 4.50	$ 7.63	$ 7.63
Consultant compensation expenses							$ 1,342,479
Investors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock issuable upon exercise warrants	500,000
Warrant, exercise price	$ 6.28
Shares issued, share based compensation shares	50,000
Stock issued, restricted stock shares	200,000
Vesting period	1 year
Share based payment award, vesting rights, percentage	50.00%
Consultant compensation expenses		$ 87,208					$ 1,342,479

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Principal balance	$ 7,627,778	$ 14,032,528
Accrued interest	78,509	163,517
Fair value adjustment	(46,329)	2,993,061
Net debt balance	7,659,958	17,189,106
2021 Notes [Member]
Short-Term Debt [Line Items]
Principal balance	7,627,778
Accrued interest	78,509
Fair value adjustment	(46,329)
Net debt balance	$ 7,659,958
2021 Convertible Notes [Member]
Short-Term Debt [Line Items]
Principal balance		13,647,341
Accrued interest		159,435
Fair value adjustment		2,993,061
Net debt balance		16,799,837
Financed Insurance [Member]
Short-Term Debt [Line Items]
Principal balance		385,187
Accrued interest		4,082
Fair value adjustment
Net debt balance		$ 389,269

SCHEDULE OF INTEREST EXPENSE DE

SCHEDULE OF INTEREST EXPENSE DEBT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Disclosure [Abstract]
Stated interest accrual	$ 2,004	$ 109,381
Debt discount amortization		174,412
Total	$ 2,004	$ 283,793

SCHEDULE OF CONVERSIONS DEBT (D

SCHEDULE OF CONVERSIONS DEBT (Details)	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Short-Term Debt [Line Items]
Total shares | shares	4,708,525
Total Conversion Value | $	$ 6,372,701
Note one [Member]
Short-Term Debt [Line Items]
Conversion date	Jan. 3, 2022
Total shares | shares	535,249
Conversion price | $ / shares	$ 2.83
Total Conversion Value | $	$ 1,517,054
Note two [Member]
Short-Term Debt [Line Items]
Conversion date	Feb. 3, 2022
Total shares | shares	1,354,423
Conversion price | $ / shares	$ 1.58
Total Conversion Value | $	$ 2,145,135
Note three [Member]
Short-Term Debt [Line Items]
Conversion date	Mar. 1, 2022
Total shares | shares	2,818,853
Conversion price | $ / shares	$ 0.96
Total Conversion Value | $	$ 2,710,512

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Nov. 05, 2021	Sep. 24, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Short-Term Debt [Line Items]
Debt Instrument, Fair Value Disclosure			$ 509,190		$ 3,303,588
Loss on debt conversions			1,700,000
Proceeds from financed insurance premiums net			867,300
Interest expense			15,021	$ 347,834
Measurement Input, Control Premium [Member]
Short-Term Debt [Line Items]
Interest expense			$ 2,004
2021 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes payable, current	$ 10,600,000	$ 5,300,000
Proceeds from convertible debt	$ 9,400,000	$ 4,600,000
Debt instrument, maturity date	Aug. 4, 2023	Jun. 23, 2023
Debt instrument, interest rate			5.00%
Debt instrument original issue discount			6.00%
Payments of Stock Issuance Costs			$ 1,900,000
Legal Fees			1
Debt Instrument, Unamortized Discount			$ 900,000
[custom:PercentageOfCashSettlementPremium]			8.00%
Convertible notes payable			$ 123,220
Debt instrument, conversion price			$ 5.87
Debt instrument, convertible, terms of conversion feature			beneficial ownership limitation of 4.99%
Debt instrument, redemption, description			The number of shares to be settled shall be based on a conversion price equal to the lesser of (a) $5.87 and (b) 92% of the average of the three lowest volume-weighted average prices (“VWAP”) during the 10 consecutive trading days prior to the applicable Monthly Redemption Date. The Company may not pay the Monthly Redemption Amount in shares unless the applicable conversion price is greater than or equal to $0.78 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder
Debt instrument, redemption price, percentage			92.00%
Debt instrument conversion price per share			$ 0.78
Convertible debt			$ 5,000,000
2021 Convertible Notes Payable [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, redemption price, percentage			20.00%
2021 Convertible Notes Payable [Member] | General and Administrative Expense [Member]
Short-Term Debt [Line Items]
Debt Instrument, Fair Value Disclosure			$ 15,900,000
Gains (Losses) on Restructuring of Debt			2,800,000
Decrease in fair value of debt			$ 7,700,000

SCHEDULE OF OUTSTANDING WARRANT

SCHEDULE OF OUTSTANDING WARRANT (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	21,090,873
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	18,901,290	[1]
Warrant description	LACQ warrants	[1]
Warrant One [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 10	[1]
Warrant One [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 11.50	[1]
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	1,106,108	[2]
Exercise price | $ / shares	$ 0.96	[2]
Warrant description	Share subscription facility	[2]
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	361,158	[3]
Exercise price | $ / shares	$ 7.63	[3]
Warrant description	Convertible note	[3]
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	722,317	[4]
Exercise price | $ / shares	$ 7.63	[4]
Warrant description	Convertible note	[4]
[1]	On June 30, 2021, as a result of the closing of the Business Combination, the Company assumed a total of 18,901,290 10.00 11.50 June 30, 2026 10,000,000 8,901,290
[2]	On July 2, 2021, upon public listing of the Company’s shares, the Company issued 1,106,108 three 10.01 14.49 11.6
[3]	On September 24, 2021, the Company issued 361,158 7.63 September 23, 2026
[4]	On November 5, 2021, the Company issued 722,317 7.63 November 4, 2026

SCHEDULE OF OUTSTANDING WARRA_2

SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Millions	Nov. 05, 2021	Sep. 24, 2021	Jul. 02, 2021	Jun. 30, 2021	Mar. 01, 2022	Feb. 01, 2022	Jan. 03, 2022	Dec. 28, 2021	Aug. 03, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants issued	722,317	361,158		18,901,290
Warrants and rights outstanding, maturity date				Jun. 30, 2026
Warrants, exercise price	$ 7.63	$ 7.63			$ 0.96	$ 1.58	$ 2.83	$ 4.50
Warrants and Rights Outstanding, Term			3 years
Debt instrument expiration date	Nov. 4, 2026	Sep. 23, 2026
General and Administrative Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, exercise price			$ 10.01
Grant date fair value of warrants price per share			$ 14.49
Fair value adjustment of warrants			$ 11.6
Subscription Arrangement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants issued			1,106,108						500,000
Public Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right, outstanding				10,000,000
Private Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Remaining of cashless warrant shares				8,901,290
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, price per share				$ 10
Warrants, exercise price									$ 11.50
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, price per share				11.50
Warrants, exercise price				$ 10

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)	Mar. 31, 2022$ / shares	Nov. 05, 2021$ / shares	Sep. 24, 2021$ / shares	Jul. 02, 2021$ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years				3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	14.49
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	10
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	11.50
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.100
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.005
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants				14.49
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.26
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.29
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants				10.01
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.96
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2.83
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years				3 years
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.0104
Expected term years	2 years 4 months 2 days
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.0147
Expected term years	2 years 5 months 26 days
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants				110
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.138
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.172
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants				0.5
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		2.25	4.49
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		7.63	7.63
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years		5 years	5 years
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		0.941	0.941
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		0.010	1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.14
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	7.63
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 6 months
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	99.4
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2.4
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.14
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	7.63
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 7 months 6 days
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	98.6
Liability Classified Warrants Remeasured1 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2.4

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Preferred stock, shares authorized	1,500,000	1,500,000	1,500,000
Preferred stock par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Common stock, shares, issued		29,968,787	24,662,904
Common stock, shares outstanding		29,949,032	24,643,149
Stock issued to settlement of convertible debt	1,357,968
Stock issued to settlement amount of convertible debt	$ 5.8
Common stock issued to settlement of termination agreement	500,000
Common stock issued to settelment of underwriting costs	125,000
SPAC [Member]
Restructuring Cost and Reserve [Line Items]
Common stock, shares outstanding	6,219,268
Former Ensysce [Member]
Restructuring Cost and Reserve [Line Items]
Common stock, shares, issued	16,053,550
Stock issued during period shares purchase of assets	19,755

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Share-Based Payment Arrangement [Abstract]
Option outstanding, beginning balance | shares	4,444,068
Weighted average exercise price. beginning balance	$ 2.40
Weighted average remaining contractual term, beginning balance	6 years
Aggregate intrinsic value, beginning balance | $	$ 10,207,306
Option outstanding, granted | shares	1,986,000
Weighted average exercise price, granted	$ 4.33
Aggregate intrinsic value, granted
Option outstanding, exercised | shares
Weighted average exercise price, exercised
Option outstanding, Expired or Forfeited | shares
Weighted average exercise price, expired / forfeited
Option outstanding, ending balance | shares	6,430,068
Weighted average exercise price, ending balance	$ 3
Weighted average remaining contractual term, ending balance	7 years 7 days
Aggregate intrinsic value, ending balance | $	$ 960
Option, exercisable | shares	5,469,714
Weighted average exercise price, exercisable	$ 3.11
Weighted average remaining contractual term, exercisable	6 years 6 months 14 days
Aggregate intrinsic value, ending exercisable | $
Option vested or expected to vest | shares	6,430,068
Weighted average exercise price, vested or expected to vest	$ 3
Weighted average remaining contractual term in years, options	7 years 7 days
Aggregate intrinsic value, vested or expected to vest | $	$ 960

SCHEDULE OF SHARE-BASED PAYMENT

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)	3 Months Ended
	Mar. 31, 2022$ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend rate	0.00%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price	$ 1.08
Exercise price	$ 1.08
Expected stock price volatility	76.12%
Expected term (years)	5 years 2 months 8 days
Risk-free interest rate	1.52%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price	$ 1.61
Exercise price	$ 6.28
Expected stock price volatility	95.87%
Expected term (years)	10 years
Risk-free interest rate	2.20%

SCHEDULE OF COMMON STOCK FUTURE

SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)	Mar. 31, 2022shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock, capital shares reserved for future issuance	28,987,583
Warrant Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock, capital shares reserved for future issuance	21,090,873
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock, capital shares reserved for future issuance	6,760,068
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock, capital shares reserved for future issuance	1,136,642

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 26, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	6,430,068			4,444,068
Stock reserved for future issuance	28,987,583
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	1,986,000
Exercise price per share vested	$ 3
Weighted-average fair value per share , grant	$ 1.01
Unrecognized stock based compensation	$ 924,175
Weighted average period	1 year 7 months 6 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	927,358
Weighted-average fair value per share , grant	$ 1.04
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares	547,358
Weighted-average fair value per share, vest	$ 1.23
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)	330,000
Weighted-average fair value per share oustanding	$ 0.88
Board Of Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	1,986,000
Board Of Members [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period	0 years
Exercise price per share vested	$ 1.08
Board Of Members [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period	4 years
Exercise price per share vested	$ 6.28
General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 373,944	$ 43,820
Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 28,490	$ 0
2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	4,444,068
Stock reserved for future issuance	1,000,000		3,000,000

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share based compensation	$ 402,434	$ 43,820
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share based compensation	$ 0	$ 33,146

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] $ in Millions	3 Months Ended
	Jun. 30, 2022USD ($)shares
Subsequent Event [Line Items]
Shares issued, shares | shares	4,511,920
Proceeds from issuance of common stock | $	$ 4.3